J&J to Pay $2.2B to Settle Marketing Allegations

Johnson & Johnson and its subsidiaries have agreed to pay over $2.2 billion to resolve criminal and civil allegations that the company promoted powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients. (Nov. 4)